Iridex Q2 revenue falls as retina sales decline
IRIX•Guidance reaffirmed for 2026
The company reaffirmed its full-year 2026 revenue guidance of $51 million to $53 million and expects 2026 adjusted operating expenses of $19 million to $19.5 million.
Iridex also said it plans to increase inventory spending to secure supply chains during a headquarters move. Lower general and administrative expenses helped drive a 5% decline in operating expenses and supported positive operating cash flow.
Glaucoma growth offsets some weakness
Glaucoma product revenue rose 19% year over year, helped by about 35% growth in Cyclo G6 probe sales, according to CEO Patrick Mercer.
Iridex said retina product revenue declined because of disruptions in the Middle East and reduced sell-through in China.
Quarterly revenue falls on weaker retina sales
Iridex said second-quarter revenue fell 7% year over year as weaker retina product sales offset gains in glaucoma products.
The laser medical systems maker reported Q2 revenue of $12.60 million, missing the $13.59 million consensus estimate from one analyst. The company posted a loss per share of $0.07 and a .
